In November 2012 Vical released animal data at the 9th International Congress of the Society for Melanoma Research documenting the benefits of combining Allovectin-7 with anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies. The poster is here.
In April 2013 Provectus released data at the American Association for Cancer Research (AACR) Annual Meeting documenting the benefits of combining PV-10 with an anti-CTLA-4 antibody. The poster is here.
Vical's methodology was:
Provectus' low dose (of the anti-CTLA4 antibody) methodology was:
Allovectin's survival graph:
PV-10' low dose (of 9H10) survival graph: